In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00802542

Enrollment

400

Registered

2008-12-05

Start date

2008-11-30

Completion date

2009-01-31

Last updated

2010-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Keywords

Hypertension, blood pressure, Atacand

Brief summary

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least \<140/90 mgHg and the doctor has decided * Signed and dated Patient Informed Consent (ICF)

Exclusion criteria

* Hypersensitivity to the active substance or to any of the excipients of Atacand.

Design outcomes

Primary

Measure	Time frame
Decrease in blood pressure	once after 4 weeks

Countries

Latvia

Outcome results